ArticleBrain, behavior, & immunity - health2026
Effects of neuroinflammation and neurotrophic factors on mental health of people with axial spondyloarthritis.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mood and anxiety disturbances can aggravate axial spondyloarthritis (axSpA). This study investigated the relationship between depression, anxiety, disease activity, systemic inflammation, and neurotrophins, specifically brain-derived neurotrophic factor (BDNF) and its precursor proBDNF. Methods: Seventy-four patients with axSpA and 79 age- and sex-matched healthy controls (HCs) completed the Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). Clinical parameters included Ankylosing Spondylitis Disease Activity Score (ASDAS) with C-reactive protein (-CRP) and patient-reported outcomes (PROs). Serum concentrations of interleukin-6 (IL-6), BDNF, proBDNF, and sortilin were determined by ELISA. Results: Depression and anxiety were more prevalent in axSpA patients (13.5% and 25.7%) than in HCs (2.1%, p < 0.05 and 8.9%, p < 0.01, respectively). Both BDI-II and BAI scores correlated with ASDAS-CRP and PROs. The severity of depression symptoms did not differ by sex, whereas anxiety was higher in female than in male axSpA patients and healthy controls. Patients with depression showed a lower BDNF/proBDNF ratio and elevated CRP levels (p < 0.05). Serum BDNF levels were reduced in axSpA compared with HCs (median 160.90, IQR 127.90-236.50 vs. 195.00, IQR 150.90-279.90, p < 0.05), with significant sex-related variability (p < 0.05). In a model adjusted for age and sex, a doubling of CRP levels was associated with a 10% decrease in BDNF. ProBDNF levels were positively correlated with IL-6 and sortilin levels. Conclusion: These findings indicate that sex and systemic inflammation contribute to the psychological burden of axSpA. Effective control of inflammation may reduce mental health comorbidities, such as depression and anxiety, which are linked to worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.